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Abstract The exceptional longevity of centenarians
is due in part to inherited genetic factors, as deduced
from data that show that first degree relatives of
centenarians live longer and have reduced overall
mortality. In recent years, a number of groups have
performed genetic association studies on long-living
individuals (LLI) and young controls to identify
alleles that are either positively or negatively selected
in the centenarian population as consequence of a
demographic pressure. Many of the reported studies
have shown genetic loci associated with longevity. Of
these, with the exception of APOE, none have been
convincingly reproduced. We validated our popula-
tions by typing the APOE locus. In addition, we used
749 American Caucasian LLI, organized in two
independent tiers and 355 American Caucasian
controls in the attempt to replicate previously pub-
lished findings. We tested Klotho (KL)-VS variant
(rs952706), Cholesteryl Ester Transfer Protein
(CETP) I405V (rs5882), Paraoxonase 1 (PON1)
Q192R (rs662), Apolipoprotein C-III (APOC3)
-641C/A (rs2542052), Microsomal Transfer Protein
(MTP) -493G/T (rs2866164) and apolipoprotein E
(APOE) e2 and e4 isoforms, (rs7412 and rs429358)
haplotypes respectively. Our results show that, at
present, except for APOE, none of the selected genes
show association with longevity if carefully tested in
a large cohort of LLI and their controls, pointing to
the need of larger populations for case–control
studies in extreme longevity.
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Introduction
The frequency of centenarians in the industrialized
world is 1 in 10,000 people and this prevalence is
rapidly changing, approaching 1 in 5,000 born in the
near future (Perls 2006). The recent reduced mortality
in western countries is partly a result of recent
changes in food availability and diet (Cordain et al.
2005) and to other environmental changes, such as
reduced exposure to infection and consequent reduc-
tion in inflammation due the discovery of antibiotics
and improvement of health care. The sum of these
changes has pushed the female life expectancy in
industrialized countries to rise 3 months/year for
160 years by scoring a 4 decade increase in life
expectancy in the last 16 decades (Oeppen and
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Vaupel 2002). In addition, many other observations
point to environmental factors as modulators of
human longevity, such as the relationship between
lower burden of sickness during childhood (expressed
as reduced child mortality), a person’s birth order in
the family (as index of young age of the mother) and
survival to extreme old age (Gavrilova NS and
Gavrilov LA 2007).
On the other hand, the role of genetics in
exceptional longevity is suggested by the dramatic
reduction of centenarian sibling mortality levels
(Perls et al. 2002). We recognize that among the
phenotype traits analyzed until now, extreme longev-
ity is apparently the most complex of all, being
influenced by individual disease susceptibility and the
rate of aging. In addition, we do not know which ages
should be adopted to observe demographic pressure
that is the loss of detrimental alleles and the
enrichment of protective ones as the population age.
For example, we would not expect to capture loci that
influence longevity acting at a very old age if the
majority of the individuals chosen for the case arm
were still young. We know that genetic case control
studies are influenced by many potential bias that are
intrinsic in the design. False positive results are
mainly due to stratification (admixture in the studied
populations), lack of appropriate corrections for
multiple testing (due to unpublished negative results)
and lack of replications. False negatives are influ-
enced by small sample size and the young ages in the
case study. In addition, the identification of extreme
longevity genetic determinants relies upon the ability
to find the right genes to test among the components
of biological pathways related to aging. Following
APOE association with longevity, the most scruti-
nized pathway has been lipid metabolism. Other
strategies include the investigation of human homo-
log of longevity genes in lower eukaryotes such as
DAF genes in C. Elegans (Christensen et al. 2006)
and the SIR2 gene in S. Cerevisiae (Gartenberg
2000).
Some non-synonimous SNPs of the genes Insulin
Growth Factor-1 Receptor (IGF-1R), apolipoprotein
B (APOB), APOC3, CETP, Angiotensin I Converting
Enzyme (ACE), Interleukin 6 (IL6), PON1, Sirtuin 3
(SIRT3), Klotho and many others have also been
tested and shown to have associations with extreme
longevity. However, these associations have not been
successfully reproduced. Of the few dozen
polymorphisms tested so far by the scientific com-
munity, the only locus consistently associated with
longevity is the haplotype that determines APOE
isoforms e2 and e4 (Lewis and Brunner. 2004).
Apolipoprotein E is a polymorphic protein involved
in transport and redistribution of lipids in various
tissues (Panza et al. 2003). The two isoforms e2 and
e4 were previously associated with susceptibility to
cardiovascular and Alzheimer disease and subse-
quently were also associated with extreme longevity
(Schachter et al. 1994).
In this work, we attempted to replicate previous
reported associations using: (1) APOE as an internal
positive control to validate our populations; (2)
populations that in the previous experiments did not
show evidence of stratification (data unpublished);
(3) two large independent cohorts of LLI.
Among the several polymorphisms that have been
previously associated with longevity, we have chosen
the association studies that in our opinion needed
further clarification.
The SNPs tested in this paper are -493G/T MTP,
APOE e2 (TT) and e4 (CC) haplotypes, CETP I405V,
KL-VS, PON1 Q192R and -641 C/A APOC3.
MTP assembles very low density lipoprotein
(VLDL) in the liver and regulate the chilomicrons
intestinal absorption. A sib-pair analysis strategy was
adopted to identify a locus at D4S1564 (Puca et al.
2001) that was subsequently investigated with hap-
lotype based associations on 875 polymorphisms that
identified a -493G/T MTP variant. This variant
showed a consistent association in a second group
of 250 centenarians and 250 controls selected to
minimize the mahalanobis distance with respect to
the cases to avoid stratification (Geesaman et al.
2003) (Table 1). As for many other studies, the MTP
association has not been reproduced in Caucasian
European populations (Nebel et al. 2005; Beekman
et al. 2006,) (Table 1).
Mice homozygous for severely hypomorphic
alleles of the Klotho gene showed features of
accelerated aging (Kuro-o et al. 1997), while trans-
genic mice over-expressing the gene were long-living
(Kurosu et al. 2005), making this gene an appealing
candidate for human genetic association studies. The
heterozygous Klotho variant KL-VS stretch (that
contain six polymorphisms) in a Bohemian Czech
population was increased in the elderly (protective
effect) while the homozygous form was decreased
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(detrimental effect) (Arking et al. 2002). The protec-
tive effect of the heterozygous state was not
corroborated in a second population from the Balti-
more WHAS and BWIS studies, stratified by race,
while the protective role of the homozygous for VS
genotype was confirmed (Arking et al. 2002).
A follow-up study on Ashkenazi-Jewish popula-
tions replicated the heterozygous advantage but not
the homozygous disadvantage (Arking et al. 2005)
(Table 2).
Individuals with exceptional longevity have shown
significantly larger low density lipoprotein (LDL) and
high density lipoprotein (HDL) particle sizes (Barzilai
et al. 2003) and consequently CETP, which determines
lipid particle size (Arai et al. 2000), was investigated in
the above mentioned Ashkenazi-Jewish populations.
Among the few SNPs tested, the homozygous GG
genotype of the CETP I405V polymorphism (that
correspond to VV), increased in centenarians and
centenarian offspring (Barzilai et al. 2003). A follow
up study on European centenarians did not replicate the
association (Cellini et al. 2005) (Table 2).
APOC3 is a major component of very LDLs and a
minor component of HDL. In a recent study,
Ashkenazi-Jewish populations were genotyped for
66 SNPs in 33 candidate genes related to cardiovas-
cular diseases. Among these, APOC3 -641CC
genotypes were more frequent among long-living
individuals. The CC carriers had lower prevalence of
hypertension and greater insulin sensitivity (Atzmon
et al. 2006) (Table 2).
Q192R variant of PON1 was selected for its role in
regulating LDL oxidation. This polymorphism
showed a controversial association with longevity,
being sometimes reported as increased (protective) in
centenarian populations, and sometimes decreased
(detrimental) (Rea et al. 2004) (Table 2).
The results reported in this study hopefully clarify
the need of using large populations to avoid false
positives and identify true associations with longev-
ity, like APOE.
Methods
Subjects
Group I: 381 US LLI (309 females and 79 males, mean
age 101.7 years [age range 93–111; Confidence inter-
val ±9.3]); group II: 368 US LLI (174 females and 194
males, mean age 95.9 years [age range 93–105;
Confidence interval ±8.7]) and 355 anonymous con-
trols, self-identified as ‘‘Caucasian’’ and\35 years of
age (191 females and 164 males, mean age 27.4 years
[age range 0–35; Confidence interval ±7.6]). LLI data
collected included health and socio-demographic his-
tories, proof of age, usually in the form of a birth
certificate, a three-generation pedigree, and measures
to assess functional independence and cognitive status.
The subjects were selected among the general
population by different strategies, contacted by mail
or telephonically, and properly consented.
The institutional review board granted approval
for this study and all subjects involved signed an
informed consent form. This study was conducted in
accordance with the ethical principles that have their
origins in the Declaration of Helsinki. Individuals
were identified and recruited by a variety of methods
Table 1 Allele frequencies in reported studies of microsomal triglycerid transfer protein
MTP (-493 G/T) (Ref)a Nationality LLIb Agec Offspring Controls Age Allele frequencyd (%) P value
G C
Geesaman et al. (2003) U.S. Caucasian 175 100.8 183 38.6 26 vs 33 74 vs 67 0.039
U.S. Caucasian 244 100.8 231 38.6 24 vs 32 76 vs 68 0.029
French 559 103.1 552 51.2 25 vs 26 75 vs 74 0.54
Nebel et al. (2005) German 370 102 540 67 28 vs 25 72 vs 75 0.28
German 1033 98.2 540 67 26 vs 25 73 vs 75 0.34
Beekman et al. (2006) Caucasian 525 251 59 27 vs 24 73 vs 76 0.41
Caucasian 379 94 251 59 26 vs 24 74 vs 76 0.60
Caucasian 655 87 244 31 24.9 vs 24 75.1 vs 76 0.64
Abbreviations: a: reference; b: long living individuals; c: refer to mean age; d: %centenarians vs %controls
Biogerontology (2008) 9:85–92 87
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including institutional web sites, direct mailings, and
advertisements in newspapers targeting potential
participants or organizations involved with the aging
community.
DNA isolation and genotyping
Centenarian and control DNA was isolated from
whole blood using a Qiamp DNA blood Midikit
(Qiagen) according to the manufacturer’s protocol.
Genotyping was performed using Taqman Assay
(Applied Biosystems). PCRs and and post-PCR
fluorescence measurements were carried out on an
ABI7900 (Applied Biosystems). For genotyping,
cluster plots were made of the fluorescent labels
using SDS software (v2.2 Applied Biosystems). Spots
falling outside a cluster were labelled as undeter-
mined. Standard quality control procedures were
applied such us duplications of the DNA extractions
and comparisons of the new aliquots with plated
DNA by SNP typing.
Statistical analysis
The chi-square test was performed using the statis-
tical package Stata ve 9.1 for a comparison of the
allele and genotype frequencies between the groups.
We used a subroutine GENHW to estimate allele,
genotype frequencies and disequilibrium coefficients
which performs asymptotic Hardy-Weinberg (HW)
equilibrium tests.
For the case–control genetic studies was used
GENCC that calculates the p-value and the confi-
dence interval (95%) of the odds ratio. A p-value less
than 0.05 was considered the threshold for statistical
significance. The subroutine TABULATE was used
to produce one-way tables of frequency counts along
with measures of association. The haplotype associ-
ation test between cases and controls was per-
formed using Haploview 3.2 software. (http://www.
broad.mit.edu/personal/jcbarret/haploview/index.php)
(Barret et al. 2005).
Results
In the present study we have genotyped 749 LLI
(divided in two groups of samples) and 355 controls
from USA for seven SNP in the genes supposedly
associated with longevity.
The analysis of APOE e2 (TT haplotype, Cys112-
Cys158) and e4 (CC haplotype, Arg112-Arg158)
isoforms (rs7412 and rs429358) showed, as expected,
that isoform e2 is enriched and isoform e4 is depleted
in centenarians compared to controls (Table 3).
-493G/T MTP polymorphism was genotyped using
the perfectly correlated SNP rs2866164 (Geesaman
et al. 2003). The first comparison (LLI group I versus
controls) shows a statistically significant decrease in
the frequency of the minor allele and the genotype
GG in centenarians compared to control population,
similar to our previous report (Geesaman et al. 2003)
(Table 4). In the second comparison (LLI group II
versus controls) the association did not approach
significance. Due to other reports that show a
difference in control allele frequency, we genotyped
an additional 156 controls (mean age 30.2 years). By
including these controls the association disappeared
(Table 4).
The homozygous GG (that corresponds to VV) for
CETP I405V (rs5882) shows no differences in
frequency among cases and controls (Table 5). This
is contrary to the original data published (Arai et al.
2000), but is in accordance with a subsequent attempt
to reproduce the results in Italian populations (Cellini
et al. 2005) (Table 2).
KL-VS variant (rs952706), PON1 Q192R (rs662),
and -641C/A APOC3 (rs2542052) showed the same
distributions of allele and genotype frequencies
between cases and controls (Table 5), not supporting
previous reports (Table 2). In addition, we combined
the analysis of group I and II (Table 5) to see if a
modest effect could be detected by a larger popula-
tion set. None of the association tests supported the
original findings, including -493G/T MTP, and
despite a nominal p value of p = 0.04 (p = 0.08/2
being the hypothesis tested one-way: cases minor
allele frequency \ control minor allele frequency),
Table 3 APOE e4 haplotype frequencies
ApoE
isoforms
LLIa vs controls
frequencies
Chi-
square
P value
US group I e4 0.055 vs 0.118 19.419 0.0000105
US group II e4 0.067 vs 0.122 12.968 0.0003
Abbreviations: a: long living individuals
Biogerontology (2008) 9:85–92 89
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the association test did not pass the level of signif-
icance after Bonferroni correction for multiple
testing.
Discussion
Many case control studies for exceptional longevity
have been published in the recent years, and, with the
exception of APOE, none of the initial findings have
been consistently reproduced. In an attempt to shed
light on longevity variants, we selected some of the
SNPs previously reported to be associated with
longevity. To avoid false positive associations we
decided to genotype two tiers of centenarians and one
of controls, to minimize eventual admixture among
the centenarians. To address the problem of false
negative results (lack of power), we have run the
study on large set of samples (380) with average ages
of cases above 95 years to capture eventual alleles
that confer advantage or disadvantage at very old
ages. The results of our analysis show a consistent
association of APOE e4 with longevity while the
analysis of Klotho KL-VS variant (rs952706), CETP
I405V (rs5882), PON1 Q192R (rs662), -641C/A
APOC3 (rs2542052) and -493G/T MTP (rs2866164)
showed no associations with exceptional longevity.
To be noted, we had to run additional 156 controls
for -493G/T MTP to disentangle the incongruent
reports of the other groups that showed no
association.
Overall, these results indicate that, for the excep-
tion of APOE, some of the previous attempts to
identify genes influencing longevity are not
replicable.
An explanation on why so many findings are not
replicated by other studies could be that reported
associations, due to stratification by age between
cases and controls, instead of pointing to longevity
enabling polymorphisms, select polymorphisms that
have changed in frequency in younger generations
due to recent immigration. This could be especially
true in the case of polymorphisms that show a great
difference in allele frequencies among ethnicities and
so more sensitive to undetected mild stratification. It
has to be said that, despite the above mentioned
reasonable theories, our initial analysis of 450
nonagenarians and 450 young controls with 317
thousand SNPs did not show any stratificationT
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(unpublished data), in agreement with other studies
(Cardon and Palmer 2003). Our data confirm the
difficulty in replicating previous associations with
human longevity. The use of small sample sizes and
over interpretation of marginal results in the initial
findings, the interpopulation heterogeneity of gene–
environment and gene–gene interactions and the
subtle differences in the selected phenotypes are
possible explanations for such discrepancies (Cardon
and Palmer 2003).
Table 5 Genotype and allele frequencies of PON1, Klotho, CETP and ApoC3
LLIa LLIa Controls
Group I Group II Group I + II
PON1 (Q192R) (350)b (360)b (710)b (351)b
GG (%) 9.8 10.2 10 11
AG (%) 40.8 39.7 40.2 39.1
AA (%) 49.3 50 49.6 49.8
P value genotype 0.477 0.933 0.849
G (%) 30.3 30.1 30.2 30.7
A (%) 69.7 69.9 69.8 69.3
P value allele 0.861 0.816 0.814
Odds ratio (95% C.I.c) 1.0 (0.81–1.27) 0.97 (0.77–1.21) 0.97 (0.80–1.18)
KLOTHO (KL-VS) (345)b (363)b (708)b (332)b
GG (%) 67.8 76.4 73 72.5
AG (%) 28.1 21.7 24 25.6
AA (%) 4.1 1.8 3 1.8
P value genotype 0.146 0.235 0.350
G (%) 81.9 88.1 85.1 85.4
A (%) 18.1 11.9 14.9 14.6
P value allele 0.081 0.2437 0.721
Odds ratio (95% C.I.c) 1.29 (0.96–1.72) 0.79 (0.58–1.08) 1.04 (0.80–1.36)
CETP (I405V) (361)b (361)b (722)b (348)b
GG (%) 9.1 11.3 10.2 11.4
AG (%) 40.4 41.2 40.8 47.4
AA (%) 50.4 47.4 48.9 41
P value genotype 0.041 0.19 0.050
G (%) 29.4 32 30.6 35.2
A (%) 70.6 68 69.4 64.8
P value allele 0.018 0.188 0.0335
Odds ratio (95% C.I.c) 1.3 (1.04–1.63) 1.15 (0.93–1.43) 0.81 (0.67–0.98)
APOC3 (–641 C/A) (356)b (357)b (713)b (354)b
CC (%) 11.5 13.7 12.7 16.1
AC (%) 48 46.5 47.3 44
AA (%) 40.4 39.6 39.9 39.9
P value genotype 0.189 0.638 0.289
A (%) 64.5 63 63.6 61.9
C (%) 35.5 37 36.4 38.1
P value allele 0.309 0.672 0.4103
Odds ratio (95% C.I.c) 0.89 (0.72–1.10) 0.95 (0.77–1.18) 0.92 (0.76–1.11)
Abbreviations: a: long living individuals b: number of samples; c: confidence interval
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